Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia

Maria Gavriatopoulou; Ioannis Ntanasis‐Stathopoulos; Vasiliki Spiliopoulou; Charalampos Filippatos; Marie Christine Kyrtsonis; Nikolaos Giannakoulas; Emmanouil Spanoudakis; Sosanna Delimpasi; Michalis Michael; Stavroula Giannouli; Georgia Kaiafa; Eirini Katodritou; Evangelos Terpos; Meletios A Dimopoulos; Efstathios Kastritis

doi:10.1016/j.clml.2025.06.007

Related publications

Article2018

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Maria Gavriatopoulou, Efstathios Kastritis, Ioannis Ntanasis‐Stathopoulos, Marie‐Christine Kyrtsonis, Argiris Symeonidis, Evdoxia Hatjiharissi, Panagiotis Repousis, Nikolaos Giannakoulas, Emmanouil Spanoudakis, Sossana Delibasi, Evridiki Michali, Michalis D Michael, Amalia Vassou, Stavroula Giannouli, Michail Iskas, Georgia Kaiafa, Panagiotis Tsirigotis, Anastasia Pouli, Elina Vervessou, Dimitrios Christoulas, Eirini Katodritou, Evangelos Terpos, Meletios A Dimopoulos

Article2007

Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.

Efstathios Kastritis, Evangelos Eleftherakis-Papaiakovou, Magdalini Migkou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas, Marie Christine Kyrtsonis, Nicolaos Anagnostopoulos, Sossana Delimpassi, Argiris Symeonidis, Meletios A Dimopoulos

Article2013

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years

Efstathios Kastritis, Marie‐Christine Kyrtsonis, Evdoxia Hatjiharissi, Argiris Symeonidis, Amalia Vassou, Panagiotis Repousis, Sosana Delimpasi, Anastasia Sioni, Eurydiki Michalis, Michalis Michael, Elina Vervessou, Ekaterini Stefanoudaki, Michael Voulgarelis, Costas Tsatalas, Evangelos Terpos, Meletios A Dimopoulos

Article2006

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A Dimopoulos, Athanasios K. Anagnostopoulos, Marie Christine Kyrtsonis, Constantinos Tsatalas, Garyfallia Kokkini, Panagiotis P. Repoussis, Athanasios Zomas, Argiris Symeonidis, Evridiki Michali, Nikolaos Athanasios Anagnostopoulos, Evangelos Terpos, T. Economopoulos, Gerasimos Pangalis

Article2013

Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom’s Macroglobulinemia

Efstathios Kastritis, Evangelos Terpos, Ioannis Papassotiriou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Michail Mazarakis, Maria Gavriatopoulou, Μαρία Ρούσσου, Meletios A Dimopoulos

Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia

Abstract

Discussion(0)

Related publications

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom’s Macroglobulinemia

Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia

Abstract

Discussion(0)

Related publications

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients &gt;75 Years

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom’s Macroglobulinemia

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years